We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Investors seeking momentum may have iShares VanEck Pharmaceutical ETF (PPH - Free Report) on radar now. The fund recently hit a new 52-week high. Shares of PPH are up approximately 21.9% from their 52-week low of $73.40/share.
But could there be more gains ahead for this ETF? Let’s take a look at the fund and the near-term outlook to get a better idea of where it might be headed.
PPH In Focus
The underlying MVIS US Listed Pharmaceutical 25 Index tracks the overall performance of companies involved in pharmaceuticals, including pharmaceutical research and development as well a production, marketing and sales of pharmaceuticals. The fund charges 36 bps in fees.
Why The Move?
The healthcare sector is a foundation of any economy, providing essential services irrespective of market conditions. From pharmaceutical giants developing life-saving drugs to companies advancing medical technologies, the healthcare sector offers a breadth of investment opportunities. Amid ongoing challenges about the geopolitical risks and the uncertainty about the timing of the likely Fed rate cuts, this healthcare ETF offers value and safe proposition.
More Gains Ahead?
The fund has a positive weighted alpha of 18.30. So, there is a decent outlook ahead for those who want to ride this surging ETF a shade further.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Pharma ETF (PPH) Hit a 52-Week High
Investors seeking momentum may have iShares VanEck Pharmaceutical ETF (PPH - Free Report) on radar now. The fund recently hit a new 52-week high. Shares of PPH are up approximately 21.9% from their 52-week low of $73.40/share.
But could there be more gains ahead for this ETF? Let’s take a look at the fund and the near-term outlook to get a better idea of where it might be headed.
PPH In Focus
The underlying MVIS US Listed Pharmaceutical 25 Index tracks the overall performance of companies involved in pharmaceuticals, including pharmaceutical research and development as well a production, marketing and sales of pharmaceuticals. The fund charges 36 bps in fees.
Why The Move?
The healthcare sector is a foundation of any economy, providing essential services irrespective of market conditions. From pharmaceutical giants developing life-saving drugs to companies advancing medical technologies, the healthcare sector offers a breadth of investment opportunities. Amid ongoing challenges about the geopolitical risks and the uncertainty about the timing of the likely Fed rate cuts, this healthcare ETF offers value and safe proposition.
More Gains Ahead?
The fund has a positive weighted alpha of 18.30. So, there is a decent outlook ahead for those who want to ride this surging ETF a shade further.